Latest Updates

Five Companies Using AI to Fight Coronavirus

Deep learning models predict old and new drugs that might successfully treat COVID-19. Read More

Read more

NEWS

Deargen Predicted Potential Antivirals for The Novel Coronavirus Infection using AI

Deargen, predicted a drug with high potential for treatment of a new coronavirus (2019-nCoV) using the deep-learning technology based AI model MT-DTI. The work is published on the BioRxiv. Read More

Read more

TECH REVIEW

MolEQ, an artificial intelligence model that adjusts multiple property at the same time and optimizes small-molecule lead compounds

Deargen Presented a self-developed small-molecule lead optimization model, MolEQ (Molecule Equalizer) at the Advancing Precision Medicine Drug Development : Incorporation of Real-World Data and Other Novel Strategies Special Conference which was held from AACR on January 9 – 12. Read More

Read more

PROJECTS

First-in Class Drug Targeting DDT2 (Code Name) Transcription Factor for Primary Cancers

We introduce the process of finding key targets for primary cancers using our AI technologies such as Wx and DearTRANS. Read More

Read more

TECH REVIEW

A new state of the art drug target interaction model, Molecule Transformer based Drug Target Interaction (MT-DTI) Model.

Deargen Presented a world-class drug-protein interaction prediction model, MT-DTI (Molecule Transformer Drug Target Interaction Model). This research is published in the Journal of Machine Learning Research (JMLR). Read More

Read more

NEWS

[Press Release] Deargen, Unveil the performance Results of a New Drug-Protein Interaction Prediction Model.

Deargen Inc. Presented at MLHC 2019, “All 8 FDA-approved EGFR anticancer drugs were predicted using a database of ninety-seven million chemical compounds”. Read More

Read more

PROJECTS

Treatment of Sarcopenia using Small Molecules

Sarcopenia is a new type of age-related disease that has been newly classified as a disease since October 2016. It is defined as a disease with a reduction in skeletal muscle mass as aging progresses and there are no treatments for age-related sarcopenia that have been approved by the FDA so far. In this regard, Deargen is challenging the development of treatments for sarcopenia using small molecules. Read More

Read more

PROJECTS

Undruggable to Degradable with AI

PROTAC is known as a new platform for disease treatment that has been difficult to reach with existing biopharmaceuticals. Deargen is accelerating the development of drugs through PROTAC by rapidly and precisely searching for small molecules that can bind to the target protein. Read More

Read more

PROJECTS

Colorectal Cancer, MERTK, and Small molecular

The study of colorectal cancer has shown that MERTK (TYRO3 / AXL / MER, TAM receptor kinase family) is an important target for cancer cell immune response evasion mechanism. Thus, Deargen is researching by focusing on small molecule inhibitors. Read More

Read more

PROJECTS

ALS (Lou Gehrig), a Challenge to Radical Cure

ALS treatments that currently are being used under FDA approval have a level that relieves symptoms and slows the progression of Lou Gehrig. Deargen is challenging the development of new ALS treatments by reducing TDP-43 protein aggregation observed in more than 90% of patients with Lou Gehrig. Read More

Read more

NEWS

[Press Release] Deargen, Signed a Strategic Technology Agreement with Uppthera for Discovering PROTAC Drug Candidates using AI.

Uppthera Inc. that is a domestic PROTAC-based drug development company joined hands with Deargen Inc. that is an AI-based drug development platform company. It is going to discover PROTAC drug candidates using artificial intelligence technology. On the 7th, Uppthera Inc. and Deargen Inc. recently announced that they have signed a strategic technology partnership agreement on the AI-based PROTAC drug development. Read More

Read more

TECH REVIEW

Prediction of origin of cancer by deep-learning analysis using pan-cancer transcriptome

We introduce DEARGEN’s research results on the model that predicts the primary cancer sites (cancer metastasis prediction) through the gene expression profile (GEP). Read More

Read more

TECH REVIEW

CWx (Cascaded Wx): Technology for Prognosis Biomarker Discovery

Deargen has announced the research results on an AI technology CWx that can discover biomarkers on disease prognosis. The research achievements has been published in the journal Frontiers in Genetics. Read More

Read more

TECH REVIEW

WX: Technology for Novel Biomarker Discovery

Deargen has announced research results on an AI technology Wx that can discover novel biomarkers. Research achievements are being published in the journal of the Nature Scientific Report, and two inventions related to these have been patented. Read More

Read more

NEWS

Deargen, Selected for the TIPS Program with Genomic Data Analysis Service

Deargen was selected for the TIPS program, so it will receive a total of $600,000 in R & D expenses from the operator Medytox Venture Investment. Read More

Read more

NEWS

Genomic Data Analysis Platform ‘DearTRANS’ Beta Service Launch

Deargen launches a beta service of ‘DearTRANS’ that is a cloud-based genomic big data analysis platform that the world’s first artificial intelligence technologies are applied. Read More

Read more

NEWS

The Challenge to Conquer Cancer, Prognostic Prediction Analysis of Lung Cancer Using AI

Deargen has been selected for the 2017 National Program for Cancer Control that is hosted by the Ministry of Health and Welfare and the National Cancer Center. Deargen will develop an integrated prognostic analysis model of lung cancer using artificial intelligence by collaboration with St. Mary’s Hospital and Dankook University. Read More

Read more

NEWS

Deargen was selected as Top Performers of the NCI-CPTAC DREAM Challenge

Deargen was selected as a Top Performer of the NCI-CPTAC DREAM Proteogenomics Computational Challenges that is international Challenges for cancer proteome prediction. Details of the challenge will be published in the Nature Method. Read More

Read more

NEWS

Deargen, Won at ILSVRC 2016 (ImageNet Large Scale Visual Recognition Challenge)

Deargen was voted in the top 10 in the world at the ‘ImageNet Large Scale Visual Recognition Challenge (ILSVRC) 2016’, the Image Recognition International Competition. The error rate of 3.5% in recognition (the 4% human error rate) has attained, which shows a much improved result compared to the error rate of Microsoft Research Lab that is a last year’s winner. Read More

Read more

NEWS

[Event] DEARGEN, in ‘KOREA Pharm and Bio 2020’ Fair

DEARGEN participated in KOREA PHARM & BIO 2020 fair in KOREA and received a lot of interest. Especially for the case of COVID-19 treatment prediction using AI. Read More

Read more